Lantern Pharma Inc. (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform's capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern's growth roadmap.
This demonstration is significant because it showcases a potentially transformative technology in the costly and time-intensive field of oncology drug development. Lantern Pharma's broader AI and machine learning platform, RADR®, leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms. The company states this approach has allowed it to advance newly developed drug programs from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program, dramatically reducing traditional timelines and costs.
The briefing, featuring CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia, will provide investors with a direct look at the withZeta.ai platform's functionality. For the industry, the successful implementation of such AI co-scientists could address billion-dollar problems in oncology drug development by improving the efficiency of identifying and developing viable treatments, particularly for rare cancers which often lack research investment. The company's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.
For readers and potential investors, the event offers critical insight into Lantern Pharma's technological differentiation and future revenue strategy. The company has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus on clinical execution for CNS and brain cancers. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. The announcement was distributed via MissionIR, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. More information on MissionIR is available at https://www.MissionIR.com, with full terms of use and disclaimers at https://www.MissionIR.com/Disclaimer.
The implications of this briefing extend beyond a corporate update. It represents a tangible step in the integration of advanced AI into biopharmaceutical research, a shift that could lower drug development costs, accelerate the delivery of new therapies to patients, and open significant market opportunities. The focus on rare cancers is particularly important, as these conditions frequently have limited treatment options. By demonstrating its platform's commercial readiness, Lantern Pharma is positioning itself at the forefront of a potentially disruptive change in how cancer drugs are discovered and developed.
